The Type I Interferon Axis in Systemic Autoimmune Diseases: From Molecular Pathways to Targeted Therapy. [PDF]
Ishihara R +7 more
europepmc +1 more source
BATF2 is a glutamine-responsive tumour suppressor required for type-I interferon-dependent anti-tumour immunity. [PDF]
Gong W +34 more
europepmc +1 more source
Epigenetic lockdown of type I interferon sensing and signalling in human pluripotent cells
Holt JH +5 more
europepmc +1 more source
Autonomous STING signaling in Purkinje cells drives neurodegeneration independent of type I interferon. [PDF]
Yang K +5 more
europepmc +1 more source
Self-aggregating Lactiplantibacillus plantarum enhances type-I interferon responses via the cytosolic sensors NOD2 and cGAS. [PDF]
Solis S +6 more
europepmc +1 more source
Interleukin-36 upregulates type-I interferon responses in systemic lupus erythematosus by promoting the accumulation of self-nucleic acids. [PDF]
Welsh EJ +4 more
europepmc +1 more source
Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma. [PDF]
Cui J +18 more
europepmc +1 more source
Natural killer cells aggravate neuroinflammation through microglial type I interferon pathway activation after traumatic brain injury. [PDF]
Nie M +12 more
europepmc +1 more source
Reduced Type-I Interferon by Plasmacytoid Dendritic Cells and Asthma in School-Aged Children. [PDF]
Coenen I +14 more
europepmc +1 more source
Correction: Genetic polymorphisms in cGAS-STING-mediated type I interferon innate immune signaling pathway are associated with DLBCL. [PDF]
Zhou Q +12 more
europepmc +1 more source

